AGREEMENT ---------Lease Agreement • March 31st, 1997 • Napro Biotherapeutics Inc • Medicinal chemicals & botanical products • Michigan
ESCROW AGREEMENT THIS ESCROW AGREEMENT (this "Agreement"), dated as of March 24, 1998, is by and among NaPro BioTherapeutics, Inc., a Delaware corporation ("NaPro"), Baker Norton Pharmaceuticals, Inc., a Florida corporation ("BNP"), and U.S. Bank...Escrow Agreement • March 26th, 1998 • Napro Biotherapeutics Inc • Medicinal chemicals & botanical products • New York
January 7, 1999 To the Holders of the Senior Convertible Notes of NaPro BioTherapeutics, Inc. Gentlemen: Reference is made to (i) the Note Purchase Agreements (as amended by the January Amendment and the March Amendment (each as defined herein), the...Letter Agreement • January 15th, 1999 • Napro Biotherapeutics Inc • Medicinal chemicals & botanical products
ANDStock Purchase Agreement • October 5th, 1999 • Napro Biotherapeutics Inc • Medicinal chemicals & botanical products • Delaware
EXHIBIT 10.3 FORM OF WARRANT THIS SECURITY HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933 OR APPLICABLE STATE SECURITIES LAWS AND MAY NOT BE SOLD, OFFERED FOR SALE, TRANSFERRED, PLEDGED OR OTHERWISE DISPOSED OF UNLESS IT HAS BEEN REGISTERED...Napro Biotherapeutics Inc • August 14th, 1997 • Medicinal chemicals & botanical products
January 28, 1998 NaPro BioTherapeutics, Inc. 6304 Spine Road Unit A Boulder, Colorado 80301 Attn: Vice President and Chief Financial Officer Gentlemen: Reference is made to (i) the Note Purchase Agreements (the "Purchase Agreements") dated as of May...Napro Biotherapeutics Inc • January 30th, 1998 • Medicinal chemicals & botanical products
LEASE AGREEMENTLease Agreement • April 2nd, 2001 • Napro Biotherapeutics Inc • Medicinal chemicals & botanical products • Ohio
Exhibit 99.1Termination Agreement • March 26th, 1998 • Napro Biotherapeutics Inc • Medicinal chemicals & botanical products • New York
RECITALSEmployment Agreement • November 13th, 1998 • Napro Biotherapeutics Inc • Medicinal chemicals & botanical products • Colorado
Exhibit 4.2 January 28, 1998 NaPro BioTherapeutics, Inc. Unit A 6304 Spine Road Boulder, Colorado 80301 Attn: Vice President and Chief Financial Officer Gentlemen: Reference is made to (i) the Subscription Agreement (the "Subscription Agreement")...Napro Biotherapeutics Inc • January 30th, 1998 • Medicinal chemicals & botanical products
Annex III to Note Purchase Agreement PLEDGE AND SECURITY AGREEMENT ----------------------------- THIS PLEDGE AND SECURITY AGREEMENT, dated as of June 4, 1997 (this "Agreement"), by and between NAPRO BIOTHERAPEUTICS, INC., a Delaware corporation (the...Pledge and Security Agreement • August 14th, 1997 • Napro Biotherapeutics Inc • Medicinal chemicals & botanical products • New York
R E C I T A L SLicense Agreement • April 2nd, 2001 • Napro Biotherapeutics Inc • Medicinal chemicals & botanical products • Delaware
EXHIBIT 10.2 FORM OF NOTE THIS NOTE HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE "ACT"), OR ANY STATE SECURITIES LAWS. THE SALE TO THE HOLDER OF THIS NOTE OF THE SHARES OF COMMON STOCK ISSUABLE UPON CONVERSION OF THIS NOTE...Napro Biotherapeutics Inc • August 14th, 1997 • Medicinal chemicals & botanical products • New York
and AMERICAN STOCK TRANSFER & TRUST COMPANY, as Rights Agent RIGHTS AGREEMENT Dated as of December 12, 2006Rights Agreement • December 14th, 2006 • Tapestry Pharmaceuticals, Inc • Medicinal chemicals & botanical products • Delaware
Certificates”) will be mailed to holders of record of the Common Shares as of the close of business on the Distribution Date and such separate Right Certificates alone will evidence the Rights.
RECITALSEmployment Agreement • April 14th, 2000 • Napro Biotherapeutics Inc • Medicinal chemicals & botanical products • Colorado
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • February 6th, 2006 • Tapestry Pharmaceuticals, Inc • Medicinal chemicals & botanical products • New York
This Registration Rights Agreement (the “Agreement”) is made and entered into as of this day of , 2006 by and among Tapestry Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and the “Investors” named in that certain Purchase Agreement by and among the Company and the Investors (the “Purchase Agreement”).
Exhibit 10-40 AGREEMENT FOR SALE AND PURCHASE ------------------------------- OF NURSERY STOCK ---------------- This Agreement is made as of this 1st day of March, 1997 and is between Zelenka Nursery, Inc. of 16127 Winans, Grand Haven, MI 49417...Agreement for Sale and Purchase • March 31st, 1997 • Napro Biotherapeutics Inc • Medicinal chemicals & botanical products • Michigan
Exhibit 10.34 FORM OF SUBSCRIPTION AGREEMENT INCLUDING REGISTRATION RIGHTS NaPro BioTherapeutics, Inc. 6304 Spine Road, Unit A Boulder, Colorado 80301 Ladies and Gentlemen: The undersigned subscriber ("Subscriber") hereby tenders this Subscription...Subscription Agreement • April 2nd, 2001 • Napro Biotherapeutics Inc • Medicinal chemicals & botanical products • Delaware
SUSPENSION NOTICE (Section 10(d) of Certificate of Designations of Series C Senior Convertible Preferred Stock)Napro Biotherapeutics Inc • June 23rd, 1999 • Medicinal chemicals & botanical products
Exhibit 10.44 March 24, 1999Letter Agreement • April 1st, 1999 • Napro Biotherapeutics Inc • Medicinal chemicals & botanical products
LOAN AND SECURITY AGREEMENT BY AND BETWEEN NAPRO BIOTHERAPEUTICS, INC. AND ABBOTT LABORATORIES JULY 23, 1999Loan and Security Agreement • October 5th, 1999 • Napro Biotherapeutics Inc • Medicinal chemicals & botanical products • Illinois
CONFIDENTIAL DEVELOPMENT, LICENSE AND SUPPLY AGREEMENT BY AND BETWEEN NAPRO BIOTHERAPEUTICS, INC.Development, License and Supply Agreement • October 5th, 1999 • Napro Biotherapeutics Inc • Medicinal chemicals & botanical products • Illinois
AMENDED AND RESTATED EMPLOYMENT AGREEMENTEmployment Agreement • March 12th, 2004 • Napro Biotherapeutics Inc • Medicinal chemicals & botanical products • Colorado
THIS AGREEMENT (the "Agreement") is entered into effective as of this 22nd day of May, 2003 (the "Effective Date"), by and between NaPro BioTherapeutics, Inc., a Delaware corporation (the "Company"), and James D. McChesney, Ph.D. ("Executive"). Certain capitalized terms used in this Agreement have the meaning set forth in Paragraph 17 of this Agreement.
Exhibit 4.2 AGREEMENT IN PRINCIPLE THIS AGREEMENT IN PRINCIPLE, dated as of January 6, 1998 (this "Agreement"), by and between NAPRO BIOTHERAPEUTICS, INC., a Delaware corporation (the "Company"), and the undersigned holder (the "Holder") of one of the...Agreement in Principle • January 12th, 1998 • Napro Biotherapeutics Inc • Medicinal chemicals & botanical products • New York
March 20, 1998 NaPro BioTherapeutics, Inc. 6304 Spine Road Unit A Boulder, Colorado 80301 Attn: Vice President and Chief Financial Officer Gentlemen: Reference is made to (i) the Note Purchase Agreements (the "Purchase Agreements") dated as of May 30,...Napro Biotherapeutics Inc • April 8th, 1998 • Medicinal chemicals & botanical products
Exhibit 99.3 March 20, 1998 Leonard P. Shaykin c/o NaPro BioTherapeutics, Inc. 6304 Spine Road, Unit A Boulder, Colorado 80301 NaPro BioTherapeutics, Inc. 6304 Spine Road, Unit A Boulder, Colorado 80301 Attn: Sterling K. Ainsworth Chief Executive...Warrant Purchase Agreement • March 26th, 1998 • Napro Biotherapeutics Inc • Medicinal chemicals & botanical products
This letter will confirm that, subject to (1) the execution and delivery of this letter by Shaykin and NaPro, (2) the execution and delivery of the Termination Agreement among IVAX, Baker Norton Pharmaceuticals, Inc., D&N and NaPro, by NaPro, and (3) the payment by Shaykin to D&N of $100,000 by wire transfer of immediately available funds to an account designated by D&N within 3 business days after the date of this letter, D&N agrees to forgive the indebtedness represented by Note, to cancel the Note and deliver it to Shaykin marked "canceled," and to deliver the Warrant, which D&N is holding on Shaykin's behalf, to NaPro for cancellation.
EXHIBIT 4.6 FORM OF SUBSCRIPTION AGREEMENT DATED DECEMBER 8, 1997 SUBSCRIPTION AGREEMENT DATED AS OF DECEMBER 8, 1997 BY AND BETWEEN NAPRO BIOTHERAPEUTICS, INC.Subscription Agreement • December 16th, 1997 • Napro Biotherapeutics Inc • Medicinal chemicals & botanical products • Colorado
RECITALS:Master Agreement • August 14th, 2000 • Napro Biotherapeutics Inc • Medicinal chemicals & botanical products • New York
COMMON STOCK PURCHASE AGREEMENTCommon Stock Purchase Agreement • March 26th, 2004 • Napro Biotherapeutics Inc • Medicinal chemicals & botanical products • New York
This Common Stock Purchase Agreement (this "Agreement") is made and effective as of March 25, 2004 by and among NAPRO BIOTHERAPEUTICS, INC., a Delaware corporation (the "Company"), and the Purchasers identified in the signature pages attached hereto (each a "Purchaser", and collectively, the "Purchasers").
RIGHTS AGREEMENTRights Agreement • November 26th, 1996 • Napro Biotherapeutics Inc • Medicinal chemicals & botanical products • Delaware
March 24, 1999Napro Biotherapeutics Inc • April 1st, 1999 • Medicinal chemicals & botanical products
AMENDED AND RESTATED EMPLOYMENT AGREEMENTEmployment Agreement • April 3rd, 2007 • Tapestry Pharmaceuticals, Inc • Medicinal chemicals & botanical products • Colorado
THIS AMENDED AND RESTATED AGREEMENT (the “Agreement”) is entered into effective as of this 28th day of March, 2007 (the “Effective Date”), by and between Tapestry Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and Martin Batt (“Executive”). This Agreement amends, restates, and replaces in its entirety that employment agreement previously entered into between Tapestry and Executive as of October 28, 2005 (the “Original Agreement”). Certain capitalized terms used in this Agreement have the meaning set forth in Paragraph 17 of this Agreement.
STOCK OPTION AGREEMENT (INCENTIVE STOCK OPTION OR NONSTATUTORY STOCK OPTION)Stock Option Agreement • May 11th, 2006 • Tapestry Pharmaceuticals, Inc • Medicinal chemicals & botanical products
Pursuant to your Stock Option Grant Notice (“Grant Notice”) and this Stock Option Agreement, Tapestry Pharmaceuticals, Inc. (the “Company”) has granted you an option under its 2006 Equity Incentive Plan (the “Plan”) to purchase the number of shares of the Company’s Common Stock indicated in your Grant Notice at the exercise price indicated in your Grant Notice. Defined terms not explicitly defined in this Stock Option Agreement but defined in the Plan shall have the same definitions as in the Plan.
TAPESTRY PHARMACEUTICALS, INC. 2006 EQUITY INCENTIVE PLANStock Option Agreement • May 7th, 2007 • Tapestry Pharmaceuticals, Inc • Medicinal chemicals & botanical products
Pursuant to your Stock Option Grant Notice (“Grant Notice”) and this Stock Option Agreement, Tapestry Pharmaceuticals, Inc. (the “Company”) has granted you an option under its 2006 Equity Incentive Plan (the “Plan”) to purchase the number of shares of the Company’s Common Stock indicated in your Grant Notice at the exercise price indicated in your Grant Notice. Defined terms not explicitly defined in this Stock Option Agreement but defined in the Plan shall have the same definitions as in the Plan.
DATED AS OF NOVEMBER 8, 1996Rights Agreement • October 23rd, 2001 • Napro Biotherapeutics Inc • Medicinal chemicals & botanical products • Delaware
